Screener
BridgeBio Pharma BBIO Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's operating income?
- BridgeBio Pharma (BBIO) reported operating income of -$105.96M in Q1 2026.
- How has BridgeBio Pharma's operating income changed year-over-year?
- BridgeBio Pharma's operating income decreased by 1.5% year-over-year, from -$104.37M to -$105.96M.
- What is the long-term trend for BridgeBio Pharma's operating income?
- Over 4 years (2021 to 2025), BridgeBio Pharma's operating income has grown at a -2.4% compound annual growth rate (CAGR), from -$576.63M to -$523.41M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about BridgeBio Pharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude